INNOVENTRIC

Innoventric is an Israeli-based startup dedicated to developing medical devices for structural heart conditions, specifically targeting tricuspid regurgitation (TR). The company specializes in percutaneous heterotopic cross-caval technologies, aiming to provide solutions that are adaptable to various patient anatomies. Innoventric is committed to improving access to high-quality care for underserved populations.

The company has a strong focus on innovation, backed by a robust patent portfolio and significant funding, including a $14 million Series A round and a €2.5 million Horizon Europe grant. Innoventric's product pipeline includes the Trillium™, a pioneering cross-caval device designed for complex anatomies, the Koala™, a docking station for valve placement, and the Unica™, which caters to smaller anatomies. These devices are designed to enhance treatment options for patients with TR, expanding care beyond traditional approaches.